Blood Cancer Awareness - Exploring Multiple Myeloma and Bone Disease

Blood Cancer Awareness – Exploring Multiple Myeloma and Bone Disease

Multiple myeloma is a hematological cancer, that disrupts normal hematopoiesis and bone marrow function. It is commonly associate with anemia, renal impairment, hypercalcemia, immunodeficiency, and osteolytic bone lesions. Bone disease is a hallmark of multiple myeloma and results from an imbalance in bone remodeling, with increased osteoclast-mediated bone resorption and suppressed osteoblast activity. 

In myeloma, bone disease is a serious problem that often causes pain and pathological bone fractures at different locations (1). Despite significant advances in therapeutic strategies that have improved outcomes and prolonged survival for patients with multiple myeloma, the disease remains largely incurable (2).

In multiple myeloma, tumor progression and associated bone disease are strongly influenced by interactions within the bone marrow microenvironment. However, not all cytokines or biomarker pathways contribute equally to the pathogenesis, progression, or prognosis of the disease. Among the most relevant mediators are IL-6, a key growth and survival factor for malignant plasma cells; RANKL, a central regulator of osteoclast activation and myeloma-related bone destruction; TNF-α, a pro-inflammatory cytokine involved in tumor–microenvironment interactions; and β-crosslaps (β-CTx), a marker of bone resorption that reflects increased osteoclast activity and skeletal turnover in multiple myeloma (3).

Blood Cancer Awareness – Exploring Multiple Myeloma and Bone Disease

The RANK/RANKL/OPG Axis in Bone Remodeling

The RANK/RANKL signaling axis plays a central role in bone metabolism and osteoclast differentiation. RANKL binds to its receptor, RANK, promoting osteoclast formation, activation, and bone resorption. Osteoprotegerin (OPG) functions as a soluble decoy receptor for RANKL, competitively binding RANKL and preventing its interaction with RANK. In this way, OPG helps inhibit osteoclast-mediated bone resorption and maintain bone remodeling balance (4).

A study on “ Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy” highlights how intensive chemotherapy can affect bone metabolism in pediatric Acute Lymphoblastic Leukemia (ALL) patients (5). A key focus is the OPG/RANKL pathway, which regulates osteoclast activity and bone resorption. By assessing osteoprotegerin (OPG) and RANKL, the study helps characterize a biochemical signature of altered bone remodeling after chemotherapy. These markers are especially relevant for understanding treatment-related bone fragility and long-term skeletal health in children with ALL.

The Role of Sclerostin and DKK-1 in Bone Remodeling

Sclerostin, also known as SOST, is primarily produced by osteocytes and is recognized as an important regulator of bone formation. It acts as a soluble antagonist of the Wnt signaling pathway, a pathway that plays a central role in bone homeostasis. Suppression of Wnt signaling is associated with reduced bone formation and increased bone degradation, whereas activation of this pathway promotes osteoblast activity and bone formation.

Dickkopf-1, or DKK-1, is a secreted extracellular protein that also functions as an inhibitor of the Wnt signaling pathway. By suppressing Wnt signaling, DKK-1 inhibits osteoblast differentiation and thereby reduces bone formation. Dysregulated DKK-1 expression has been linked to disturbed bone metabolism and may contribute to cancer progression (6).

Recent research highlights DKK-1 as a key mediator in multiple myeloma-associated bone disease. The study “Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma” shows that targeting the Wnt signaling pathway, including inhibition of DKK-1, may help protect against myeloma-induced bone loss and improve bone strength in preclinical models (7). These findings underline the importance of DKK-1 as a biomarker and research target in understanding bone remodeling, skeletal complications, and potential therapeutic strategies in multiple myeloma.

Biomedica offers quality kits for the measurement of bone biomarkers:

–Osteoprotegerin (OPG) ELISA (cat. no. BI-20403)

–Soluble free RANKL ELISA (cat. no. BI-20462)

–Sclerostin (SOST) ELISA (cat.no. BI-20492)

–Bioactive Sclerostin (SOST) ELISA (cat. no. BI-20472)

–DKK-1 (Dickkopf-1) ELISA (cat.no. BI-20413)

 

 

Key highlights

• Trusted – cited in 1,000+ publications
• Reliable – validated kits following international quality guidelines
• Easy to use – color-coded, ready-to-use reagents

 

Literature

1. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities. Abduh MS. Saudi J Biol Sci. 2024 Feb;31(2):103920. doi: 10.1016/j.sjbs.2023.103920. Epub 2023 Dec 30. PMID: 38283805; PMCID: PMC10818257.
2. Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy. Fu C, Zhai Y, Yan L, Jin S, Shang J, Shi X, Wu D. Chin Med J (Engl). 2025 Oct 5;138(19):2399-2410. doi: 10.1097/CM9.0000000000003655. Epub 2025 Aug 8. PMID: 40784898; PMCID: PMC12487921.
3. The Impact of Modern Bone Markers in Multiple Myeloma: Prospective Analyses Pre and Post-First Line Treatment. Pop VS, Iancu M, Țigu AB, Adam A, Tomoaia G, Farcas AD, Bojan AS, Parvu A. Curr Issues Mol Biol. 2024 Aug 24;46(9):9330-9341. doi: 10.3390/cimb46090552. PMID: 39329904; PMCID: PMC11430338.
4. The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer. Medicina (Kaunas). De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, Fraile-Martinez O, García-Montero C, López-González L, Torres-Carranza D, García-Puente LM, Carranza ST, Álvarez-Mon MÁ, Álvarez-Mon M, Diaz R, Ortega MA. 2023 Sep 30;59(10):1752. doi: 10.3390/medicina59101752. PMID: 37893470; PMCID: PMC10608105.
5. Bone Remodeling Markers in Children with Acute Lymphoblastic Leukemia after Intensive Chemotherapy: The Screenshot of a Biochemical Signature. Muggeo P, Grassi M, D’Ascanio V, Brescia V, Fontana A, Piacente L, Di Serio F, Giordano P, Faienza MF, Santoro N. Cancers (Basel). 2023 Apr 29;15(9):2554. doi: 10.3390/cancers15092554. PMID: 37174020; PMCID: PMC10177249.
6. Dynamics of Bone Disease Biomarkers Dickkopf-1 and Sclerostin in Patients with Multiple Myeloma. Gerov V, Gerova D, Micheva I, Nikolova M, Mihaylova G, Galunska B. J Clin Med. 2023 Jul 1;12(13):4440. doi: 10.3390/jcm12134440. PMID: 37445475; PMCID: PMC10342782
7. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma. Simic MK, Mohanty ST, Xiao Y, Cheng TL, Taylor VE, Charlat O, Croucher PI, McDonald MM. J Bone Miner Res. 2023 Jun;38(6):814-828. doi: 10.1002/jbmr.4809. Epub 2023 May 25. PMID: 36987921; PMCID: PMC10947379.